{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T08:10:19Z","timestamp":1791274219524,"version":"4.1.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T00:00:00Z","timestamp":1695254400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T00:00:00Z","timestamp":1695254400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Strategic Action in Health of the Institute of Health Carlos III","award":["PIC18\/00018"],"award-info":[{"award-number":["PIC18\/00018"]}]},{"name":"Department of Regional Health of the Castilla y L\u00e9on Government","award":["GRS 1928\/A\/19"],"award-info":[{"award-number":["GRS 1928\/A\/19"]}]},{"DOI":"10.13039\/501100008431","name":"Consejer\u00eda de Educaci\u00f3n, Junta de Castilla y Le\u00f3n","doi-asserted-by":"publisher","award":["Grant VA077P17"],"award-info":[{"award-number":["Grant VA077P17"]}],"id":[{"id":"10.13039\/501100008431","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Stem Cell Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>An effective treatment for acute non-arteritic ischemic optic neuropathy (NA-AION) has not been known or proven yet. Previous studies have suggested a neuroprotective effect of allogeneic bone marrow-derived mesenchymal stem cells. This study aims to report the results of a clinical trial on patients with acute non-arteritic optic neuropathy (NA-AION) treated with an intravitreal injection of allogeneic bone marrow-derived mesenchymal stem cells (BM-MSCs) (MSV\u00ae).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We conducted a prospective, non-randomized, clinical phase-II study (Eudra CT number 2016-003029-40; ClinicalTrials.gov Registry NCT03173638) that included 5 patients with acute unilateral NA-AION diagnosed within 2\u00a0weeks after symptom onset and who received an intravitreal injection of allogeneic BM-MSCs (0.05\u00a0ml; cell concentration: 1.5\u2009\u00d7\u200910\n                      <jats:sup>6<\/jats:sup>\n                      cells\/mL). The patients underwent regular ophthalmological examinations and were followed for one year.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In this trial, allogeneic BM-MSCs appeared to be safe as no patients developed signs of acute nor chronic intraocular inflammation or a significant change in intraocular pressure, although an epiretinal membrane was developed in one patient. A retrolental aggregate formed shortly after the injection spontaneously disappeared within a few weeks in another phakic patient, leaving a subcapsular cataract. Visual improvement was noted in 4 patients, and amplitudes of P100 on the visually evoked potentials recordings increased in three patients. The retinal nerve fiber layer and macular ganglion cell layer thicknesses significantly decreased during the follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Besides the development of an epiretinal membrane in one patient, the intravitreal application of allogeneic BM-MSCs appeared to be intraocularly well tolerated. Consequently, not only NA-AION but also BM-MSCs deserve more clinical investigational resources and a larger randomized multicenter trial that would provide stronger evidence both about safety and the potential therapeutic efficacy of intravitreally injected allogeneic BM-MSCs in acute NA-AION.<\/jats:p>\n                    <jats:p>\n                      <jats:italic>Trial registration<\/jats:italic>\n                      : Safety Assessment of Intravitreal Mesenchymal Stem Cells for Acute Non-Arteritic Anterior Ischemic Optic Neuropathy (NEUROSTEM). NCT03173638. Registered June 02, 2017\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03173638\">https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03173638<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13287-023-03500-7","type":"journal-article","created":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T06:01:53Z","timestamp":1695276113000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Intravitreal allogeneic mesenchymal stem cells: a non-randomized phase II clinical trial for acute non-arteritic optic neuropathy"],"prefix":"10.1186","volume":"14","author":[{"given":"Jose C.","family":"Pastor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6463-4227","authenticated-orcid":false,"given":"Salvador","family":"Pastor-Idoate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"L\u00f3pez-Paniagua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Para","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Blazquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Murgui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ver\u00f3nica","family":"Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa M.","family":"Coco-Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,21]]},"reference":[{"key":"3500_CR1","doi-asserted-by":"publisher","first-page":"123","DOI":"10.4103\/0301-4738.77024","volume":"59","author":"SS Hayreh","year":"2011","unstructured":"Hayreh SS. Management of ischemic optic neuropathies. Indian J Ophthalmol. 2011;59:123\u201336.","journal-title":"Indian J Ophthalmol"},{"key":"3500_CR2","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.preteyeres.2008.11.002","volume":"28","author":"SS Hayreh","year":"2009","unstructured":"Hayreh SS. Ischemic optic neuropathy. Prog Retin Eye Res. 2009;28:34\u201362.","journal-title":"Prog Retin Eye Res"},{"key":"3500_CR3","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1097\/WNO.0000000000000870","volume":"39","author":"JF Rizzo 3rd","year":"2019","unstructured":"Rizzo JF 3rd. Unraveling the enigma of nonarteritic anterior ischemic optic neuropathy. J Neuro-ophthalmol. 2019;39:529\u201344.","journal-title":"J Neuro-ophthalmol"},{"key":"3500_CR4","unstructured":"Raizada K, Margolin E. Non-arteritic anterior ischemic optic neuropathy. [Updated 2021 Aug 22]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK559045\/. Accessed 21 Dec 2021."},{"key":"3500_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ncl.2016.08.003","volume":"35","author":"R Foroozan","year":"2017","unstructured":"Foroozan R. New treatments for nonarteritic anterior ischemic optic neuropathy. Neurol Clin. 2017;35:1\u201315.","journal-title":"Neurol Clin"},{"key":"3500_CR6","first-page":"78","volume":"76","author":"S Kal\u00e1bov\u00e1","year":"2020","unstructured":"Kal\u00e1bov\u00e1 S, Mare\u0161ov\u00e1 K, Karhanov\u00e1 M. Non-arteritic anterior ischaemic optic neuropathy: treatment and risk factors. Cesk Slov Oftalmol. 2020;76:78\u201387.","journal-title":"Cesk Slov Oftalmol"},{"key":"3500_CR7","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1136\/bjophthalmol-2019-314656","volume":"104","author":"SS Hayreh","year":"2020","unstructured":"Hayreh SS. Controversies on neuroprotection therapy in non-arteritic anterior ischaemic optic neuropathy. Br J Ophthalmol. 2020;104:153\u20136.","journal-title":"Br J Ophthalmol"},{"key":"3500_CR8","doi-asserted-by":"publisher","first-page":"94","DOI":"10.21037\/sci.2017.11.05","volume":"4","author":"JN Weiss","year":"2017","unstructured":"Weiss JN, Levy S, Benes SC. Stem Cell Ophthalmology Treatment Study: bone marrow derived stem cells in the treatment of non-arteritic ischemic optic neuropathy (NAION). Stem Cell Invest. 2017;4:94.","journal-title":"Stem Cell Invest"},{"key":"3500_CR9","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s00417-017-3842-3","volume":"256","author":"S Labrador Velandia","year":"2018","unstructured":"Labrador Velandia S, Di Lauro S, Alonso-Alonso ML, et al. Biocompatibility of intravitreal injection of human mesenchymal stem cells in immunocompetent rabbits. Graefes Arch Clin Exp Ophthalmol. 2018;256:125\u201334.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"3500_CR10","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.beha.2011.01.004","volume":"24","author":"A Uccelli","year":"2011","unstructured":"Uccelli A, Benvenuto F, Laroni A, et al. Neuroprotective features of mesenchymal stem cells. Best Pract Res Clin Haematol. 2011;24:59\u201364.","journal-title":"Best Pract Res Clin Haematol"},{"key":"3500_CR11","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1186\/s12974-019-1571-8","volume":"16","author":"S Dabrowska","year":"2019","unstructured":"Dabrowska S, Andrzejewska A, Lukomska B, et al. Neuroinflammation as a target for treatment of stroke using mesenchymal stem cells and extracellular vesicles. J Neuroinflammation. 2019;16:178.","journal-title":"J Neuroinflammation"},{"key":"3500_CR12","doi-asserted-by":"publisher","first-page":"2606","DOI":"10.1002\/jcp.25028","volume":"230","author":"MSH Ho","year":"2015","unstructured":"Ho MSH, Mei SHJ, Stewart DJ. The immunomodulatory and therapeutic effects of mesenchymal stromal cells for acute lung injury and sepsis. J Cell Physiol. 2015;230:2606\u201317.","journal-title":"J Cell Physiol"},{"key":"3500_CR13","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1089\/hum.2010.156","volume":"21","author":"MD Griffin","year":"2010","unstructured":"Griffin MD, Ritter T, Mahon BP. Immunological aspects of allogeneic mesenchymal stem cell therapies. Hum Gene Ther. 2010;21:1641\u201355.","journal-title":"Hum Gene Ther"},{"key":"3500_CR14","doi-asserted-by":"publisher","first-page":"e205","DOI":"10.1097\/TXD.0000000000000724","volume":"3","author":"J Garc\u00eda-Sancho","year":"2017","unstructured":"Garc\u00eda-Sancho J, S\u00e1nchez A, Vega A, et al. Influence of HLA Matching on the efficacy of allogeneic mesenchymal stromal cell therapies for osteoarthritis and degenerative disc disease. Transplant Direct. 2017;3:e205.","journal-title":"Transplant Direct"},{"key":"3500_CR15","doi-asserted-by":"crossref","unstructured":"Dominici M, Le Blanc K, Mueller I et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy.2006;8,315\u2013317.","DOI":"10.1080\/14653240600855905"},{"key":"3500_CR16","doi-asserted-by":"publisher","first-page":"4120","DOI":"10.1182\/blood-2004-04-1559","volume":"105","author":"S Aggarwal","year":"2005","unstructured":"Aggarwal S, Pitterger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood. 2005;105:4120\u20136.","journal-title":"Blood"},{"key":"3500_CR17","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.trsl.2018.11.003","volume":"206","author":"M Calonge","year":"2019","unstructured":"Calonge M, P\u00e9rez I, Galindo S, et al. A proof-of-concept clinical trial using mesenchymal stem cells for the treatment of corneal epithelial stem cell deficiency. Transl Res. 2019;206:18\u201340.","journal-title":"Transl Res"},{"key":"3500_CR18","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.pharmthera.2014.09.003","volume":"146","author":"A Moretti","year":"2015","unstructured":"Moretti A, Ferrari F, Villa RF. Neuroprotection for ischaemic stroke: current status and challenges. Pharmacol Ther. 2015;146:23\u201334.","journal-title":"Pharmacol Ther"},{"key":"3500_CR19","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.jcyt.2014.04.002","volume":"17","author":"P Wuchter","year":"2015","unstructured":"Wuchter P, Bieback K, Schrezenmeier H, et al. Standardization of good manufacturing practice-compliant production of bone marrow-derived human mesenchymal stromal cells for immunotherapeutic applications. Cytotherapy. 2015;17:128\u201339.","journal-title":"Cytotherapy"},{"key":"3500_CR20","doi-asserted-by":"publisher","first-page":"107671","DOI":"10.1016\/j.exer.2019.05.011","volume":"185","author":"S Labrador-Velandia","year":"2019","unstructured":"Labrador-Velandia S, Alonso-Alonso ML, Di Lauro S, et al. Mesenchymal stem cells provide paracrine neuroprotective resources that delay the degeneration of co-cultured organotypic neuroretinal cultures. Exp Eye Res. 2019;185:107671.","journal-title":"Exp Eye Res"},{"key":"3500_CR21","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/j.omtm.2020.05.003","volume":"13","author":"R Usategui-Mart\u00edn","year":"2020","unstructured":"Usategui-Mart\u00edn R, Puertas-Neyra K, Garc\u00eda-Guti\u00e9rrez MT, et al. Mesenchymal stem cell secretome exhibits a neuroprotective effect over in vitro retinal photoreceptor degeneration. Mol Ther Methods Clin Dev. 2020;13:1155\u201366.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"3500_CR22","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1167\/iovs.63.4.27","volume":"63","author":"R Usategui-Mart\u00edn","year":"2022","unstructured":"Usategui-Mart\u00edn R, Puertas-Neyra K, Galindo-Cabello N, et al. Retinal neuroprotective effect of mesenchymal stem cells secretome through modulation of oxidative stress, autophagy, and programmed cell death. Invest Ophthalmol Vis Sci. 2022;63:27.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"3500_CR23","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1097\/TP.0000000000001484","volume":"101","author":"DC Noriega","year":"2017","unstructured":"Noriega DC, Ardura F, Hern\u00e1ndez-Ramajo R, et al. Intervertebral disc repair by allogeneic mesenchymal bone marrow cells: a randomized controlled trial. Transplantation. 2017;101:1945\u201351.","journal-title":"Transplantation"},{"key":"3500_CR24","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1097\/TP.0000000000000678","volume":"99","author":"A Vega","year":"2015","unstructured":"Vega A, Mart\u00edn-Ferrero MA, Del Canto F, et al. Treatment of knee osteoarthritis with allogeneic bone marrow mesenchymal stem cells: a randomized controlled trial. Transplantation. 2015;99:1681\u201390.","journal-title":"Transplantation"},{"key":"3500_CR25","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1177\/0961203318804922","volume":"27","author":"J Barbado","year":"2018","unstructured":"Barbado J, Tabera S, S\u00e1nchez A, et al. Therapeutic potential of allogeneic mesenchymal stromal cells transplantation for lupus nephritis. Lupus. 2018;27:2161\u20135.","journal-title":"Lupus"},{"key":"3500_CR26","doi-asserted-by":"crossref","unstructured":"Chylack LT Jr., Wolfe JK, Singer DM, et al. The lens opacities classification system III. The longitudinal study of cataract study group. Arch Ophthalmol. 1993;111:831\u2013836.","DOI":"10.1001\/archopht.1993.01090060119035"},{"key":"3500_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10633-016-9553-y","volume":"133","author":"JV Odom","year":"2016","unstructured":"Odom JV, Bach M, Brigell M, et al. ISCEV standard for clinical visual evoked potentials: (2016 update). Doc Ophthalmol. 2016;133:1\u20139.","journal-title":"Doc Ophthalmol"},{"key":"3500_CR28","doi-asserted-by":"crossref","unstructured":"Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol. 2005;140:509\u2013516.","DOI":"10.1016\/j.ajo.2005.03.057"},{"key":"3500_CR29","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1167\/iovs.11-8306","volume":"53","author":"S Prilloff","year":"2012","unstructured":"Prilloff S, Henrich-Noack P, Sabel BA. Recovery of axonal transport after partial optic nerve damage is associated with secondary retinal ganglion cell death in vivo. Invest Ophthalmol Vis Sci. 2012;53:1460\u20136.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"3500_CR30","doi-asserted-by":"publisher","first-page":"115","DOI":"10.2174\/1570161115666161104095522","volume":"15","author":"D Radak","year":"2017","unstructured":"Radak D, Katsiki N, Resanovic I, et al. Apoptosis and acute brain ischemia in ischemic stroke. Curr Vasc Pharmacol. 2017;15:115\u201322.","journal-title":"Curr Vasc Pharmacol"},{"key":"3500_CR31","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3390\/medicines7040016","volume":"7","author":"JN Weiss","year":"2020","unstructured":"Weiss JN, Levy S. Stem Cell Ophthalmology Treatment Study (SCOTS): bone marrow-derived stem cells in the treatment of age-related macular degeneration. Medicines (Basel). 2020;7:16.","journal-title":"Medicines (Basel)"},{"key":"3500_CR32","doi-asserted-by":"publisher","first-page":"18","DOI":"10.21037\/sci.2018.04.02","volume":"5","author":"JN Weiss","year":"2018","unstructured":"Weiss JN, Levy S. Stem Cell Ophthalmology Treatment Study: bone marrow derived stem cells in the treatment of retinitis pigmentosa. Stem Cell Invest. 2018;5:18.","journal-title":"Stem Cell Invest"},{"key":"3500_CR33","doi-asserted-by":"publisher","first-page":"41","DOI":"10.21037\/sci.2019.11.01","volume":"6","author":"JN Weiss","year":"2019","unstructured":"Weiss JN, Levy S. Stem Cell Ophthalmology Treatment Study (SCOTS): bone marrow derived stem cells in the treatment of dominant optic atrophy. Stem Cell Invest. 2019;6:41.","journal-title":"Stem Cell Invest"},{"key":"3500_CR34","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.ophtha.2007.05.027","volume":"115","author":"SS Hayreh","year":"2008","unstructured":"Hayreh SS, Zimmerman MB. Nonarteritic anterior ischemic optic neuropathy: natural history of visual outcome. Ophthalmology. 2008;115:298\u2013305.","journal-title":"Ophthalmology"},{"key":"3500_CR35","doi-asserted-by":"publisher","first-page":"2667","DOI":"10.1007\/s10792-020-01448-8","volume":"40","author":"HM Huang","year":"2020","unstructured":"Huang HM, Wu PC, Kuo HK, et al. Natural history and visual outcome of nonarteritic anterior ischemic optic neuropathy in Southern Taiwan: a pilot study. Int Ophthalmol. 2020;40:2667\u201376.","journal-title":"Int Ophthalmol"},{"key":"3500_CR36","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1016\/j.ophtha.2007.05.042","volume":"114","author":"I Contreras","year":"2007","unstructured":"Contreras I, Noval S, Rebolleda G. Mu\u00f1oz-Negrete FJ (2007) Follow-up of nonarteritic anterior ischemic optic neuropathy with optical coherence tomography. Ophthalmology. 2007;114:2338-2344.e2331.","journal-title":"Ophthalmology"},{"key":"3500_CR37","doi-asserted-by":"publisher","first-page":"107865","DOI":"10.1016\/j.exer.2019.107865","volume":"190","author":"A Yazdanyar","year":"2020","unstructured":"Yazdanyar A, Zhang P, Dolf C, et al. Effects of intravitreal injection of human CD34+ bone marrow stem cells in a murine model of diabetic retinopathy. Exp Eye Res. 2020;190:107865.","journal-title":"Exp Eye Res"},{"key":"3500_CR38","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.exer.2013.10.023","volume":"118","author":"A Tzameret","year":"2014","unstructured":"Tzameret A, Sher I, Belkin M, et al. Transplantation of human bone marrow mesenchymal stem cells as a thin subretinal layer ameliorates retinal degeneration in a rat model of retinal dystrophy. Exp Eye Res. 2014;118:135\u201344.","journal-title":"Exp Eye Res"},{"key":"3500_CR39","doi-asserted-by":"crossref","unstructured":"Johnson MW. Perspective. Posterior vitreous detachment: evolution and complications of its early stages. Am J Ophthalmol. 2010;149:371\u2013382.","DOI":"10.1016\/j.ajo.2009.11.022"},{"key":"3500_CR40","doi-asserted-by":"publisher","first-page":"192582","DOI":"10.1155\/2013\/192582","volume":"2013","author":"M Joshi","year":"2013","unstructured":"Joshi M, Agrawal S, Christoforidis DB. Inflammatory mechanisms of idiopathic epiretinal membrane formation. Mediators Inflamm. 2013;2013:192582.","journal-title":"Mediators Inflamm"},{"key":"3500_CR41","doi-asserted-by":"crossref","unstructured":"Christakopoulosa C, Cehofskib LJ, SR Christensena SR, et al. Proteomics reveals a set of highly enriched proteins in epiretinal membrane compared with inner limiting membrane. Exp Eye Res. 2019; 186:107722.","DOI":"10.1016\/j.exer.2019.107722"},{"issue":"10","key":"3500_CR42","doi-asserted-by":"publisher","first-page":"3006","DOI":"10.1002\/stem.2095","volume":"33","author":"A Tassoni","year":"2015","unstructured":"Tassoni A, Gutteridge A, Barber AC, et al. Molecular mechanisms mediating retinal reactive gliosis following bone marrow mesenchymal stem cell transplantation. Stem Cells. 2015;33(10):3006\u201316.","journal-title":"Stem Cells"},{"key":"3500_CR43","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1038\/nn1088","volume":"6","author":"R Kinouchi","year":"2003","unstructured":"Kinouchi R, Takeda M, Yang L, et al. Robust neural integration from retinal transplants in mice deficient in GFAP and vimentin. Nat Neurosci. 2003;6:863\u20138.","journal-title":"Nat Neurosci"},{"key":"3500_CR44","doi-asserted-by":"publisher","first-page":"5970","DOI":"10.1167\/iovs.09-4504","volume":"51","author":"M Chen","year":"2010","unstructured":"Chen M, Chen Q, Sun X, et al. Generation of retinal ganglion-like cells from reprogrammed mouse fibroblasts. Invest Ophthalmol Vis Sci. 2010;51:5970\u20138.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"3500_CR45","doi-asserted-by":"publisher","first-page":"8344","DOI":"10.1038\/srep08344","volume":"5","author":"T Tanaka","year":"2015","unstructured":"Tanaka T, Yokoi T, Tamalu F, et al. Generation of retinal ganglion cells with functional axons from human induced pluripotent stem cells. Sci Rep. 2015;5:8344.","journal-title":"Sci Rep"},{"key":"3500_CR46","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1634\/stemcells.2007-0898","volume":"26","author":"S Singhal","year":"2008","unstructured":"Singhal S, Lawrence JM, Bhatia B, et al. Chondroitin sulfate proteoglycans and microglia prevent migration and integration of grafted Muller stem cells into degenerating retina. Stem Cells. 2008;26:1074\u201382.","journal-title":"Stem Cells"},{"key":"3500_CR47","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1073\/pnas.1212677110","volume":"110","author":"AC Barber","year":"2013","unstructured":"Barber AC, Hippert C, Duran Y, et al. Repair of the degenerate retina by photoreceptor transplantation. Proc Natl Acad Sci USA. 2013;110:354\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3500_CR48","doi-asserted-by":"publisher","first-page":"100647","DOI":"10.1016\/j.ajoc.2020.100647","volume":"18","author":"KT Khine","year":"2020","unstructured":"Khine KT, Albini TA, Lee RK. Chronic retinal detachment and neovascular glaucoma after intravitreal stem cell injection for Usher Syndrome. Am J Ophthalmol Case Rep. 2020;18:100647.","journal-title":"Am J Ophthalmol Case Rep"},{"key":"3500_CR49","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1056\/NEJMoa1609583","volume":"376","author":"AE Kuriyan","year":"2017","unstructured":"Kuriyan AE, Albini TA, Townsend JH, et al. Vision loss after intravitreal injection of autologous \u201cstem cells\u201d for AMD. N Engl J Med. 2017;376:1047\u201353.","journal-title":"N Engl J Med"},{"key":"3500_CR50","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.preteyeres.2016.10.002","volume":"56","author":"SS Park","year":"2017","unstructured":"Park SS, Moisseiev E, Bauer G, et al. Advances in bone marrow stem cell therapy for retinal dysfunction. Prog Retin Eye Res. 2017;56:148\u201365.","journal-title":"Prog Retin Eye Res"},{"key":"3500_CR51","doi-asserted-by":"publisher","first-page":"617377","DOI":"10.3389\/fnins.2020.617377","volume":"14","author":"Y Lin","year":"2021","unstructured":"Lin Y, Ren X, Chen Y, et al. Interaction between mesenchymal stem cells and retinal degenerative microenvironment. Front Neurosci. 2021;14:617377.","journal-title":"Front Neurosci"},{"key":"3500_CR52","doi-asserted-by":"publisher","first-page":"3162478","DOI":"10.1155\/2019\/3162478","volume":"2019","author":"R Nuzzi","year":"2019","unstructured":"Nuzzi R, Tridico F. Perspectives of autologous mesenchymal stem-cell transplantation in macular hole surgery: a review of current findings. J Ophthalmol. 2019;2019:3162478.","journal-title":"J Ophthalmol"},{"key":"3500_CR53","doi-asserted-by":"publisher","first-page":"58","DOI":"10.4103\/2008-322X.200164","volume":"12","author":"L Satarian","year":"2017","unstructured":"Satarian L, Nourinia R, Safi S, et al. Intravitreal injection of bone marrow mesenchymal stem cells in patients with advanced retinitis pigmentosa; a safety study. J Ophthalmic Vis Res. 2017;12:58\u201364.","journal-title":"J Ophthalmic Vis Res"},{"key":"3500_CR54","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.preteyeres.2015.07.005","volume":"51","author":"JC Pastor","year":"2016","unstructured":"Pastor JC, Rojas J, Pastor-Idoate S, et al. Proliferative vitreoretinopathy: a new concept of disease pathogenesis and practical consequences. Prog Retin Eye Res. 2016;51:125\u201355.","journal-title":"Prog Retin Eye Res"},{"key":"3500_CR55","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/nprot.2007.4","volume":"2","author":"RN Agrawal","year":"2007","unstructured":"Agrawal RN, He S, Spee C, et al. In vivo models of proliferative vitreoretinopathy. Nat Protoc. 2007;2:67\u201377.","journal-title":"Nat Protoc"},{"key":"3500_CR56","doi-asserted-by":"publisher","first-page":"166181","DOI":"10.1016\/j.bbadis.2021.166181","volume":"1867","author":"AMK Chandran","year":"2021","unstructured":"Chandran AMK, Coltrini D, Belleri M, et al. Vitreous from idiopathic epiretinal membrane patients induces glial-to-mesenchymal transition in M\u00fcller cells. Biochim Biophys Acta Mol Basis Dis. 2021;1867:166181.","journal-title":"Biochim Biophys Acta Mol Basis Dis"}],"container-title":["Stem Cell Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-023-03500-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13287-023-03500-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-023-03500-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,19]],"date-time":"2023-11-19T06:38:55Z","timestamp":1700375935000},"score":1,"resource":{"primary":{"URL":"https:\/\/stemcellres.biomedcentral.com\/articles\/10.1186\/s13287-023-03500-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,21]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["3500"],"URL":"https:\/\/doi.org\/10.1186\/s13287-023-03500-7","relation":{},"ISSN":["1757-6512"],"issn-type":[{"value":"1757-6512","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,21]]},"assertion":[{"value":"28 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Clinical Research Ethics Committee of the Valladolid East Health Area and the Spanish Agency for Medicine and Medical Devices (AEMPS) approved the study protocol, which followed European laws and the Declaration of Helsinki with its subsequent amendments. project title; ESTUDIO FASE I DE LA SEGURIDAD DE LAS C\u00c9LULAS MADRE MESENQUIMALES MSV\u00ae EN INYECCI\u00d3N INTRAV\u00cdTREA PARA EL TRATAMIENTO DE PACIENTES CON NEUROPAT\u00cdA \u00d3PTICA ISQU\u00c9MICA ANTERIOR NO ARTER\u00cdTICA AGUDA. C\u00d3DIGO PROMOTOR: IOBA-01-2016 N\u00ba EUDRA: 2016-001032-35, approval number; CASVE 16-261, date of approval; 01-06-2016).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no potential conflicts of interest with respect to the research, authorship, and\/or publication of this article. Presented in part at the VII International Congress of Research in Retina and Vision, June 24\u201326, 2021, Murcia, Spain, and the LIII Congress of Andalusian Society of Ophthalmology, June 24, 2021, Sevilla, Spain.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"261"}}